CoChat
Sign Up
Cited by 379Hepatitis C virus researchDrug-Induced Hepatotoxicity and ProtectionLiver physiology and pathology

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients: Mitoquinone and liver damage

Gane, Edward J., Weilert, Frank, Orr, David W., Keogh, Geraldine F., Gibson, Michael, Lockhart, Michelle M., Frampton, Christopher M., Taylor, Kenneth M., Smith, Robin A. J., Murphy, Michael P.·2010·Liver International
DOI 10.1111/j.1478-3231.2010.02250.x
Open this paper in CoChat — free account

Abstract

BACKGROUND: Increased oxidative stress and subsequent mitochondrial damage are important pathways for liver damage in chronic hepatitis C virus (HCV) infection; consequently, therapies that decrease mitochondrial oxidative damage may improve outcome. The mitochondria-targeted anti-oxidant mitoquinone combines a potent anti-oxidant with a lipophilic cation that causes it to accumulate several-hundred fold within mitochondria in vivo. AIMS: In this phase II study, we investigated the effect of oral mitoquinone on serum aminotransferases and HCV RNA levels in HCV-infected patients. METHODS: Thirty HCV patients who were either non-responders or unsuitable candidates for standard-of-care (pegylated interferon plus ribavirin) were randomized to receive mitoquinone (40 or 80 mg) or placebo once daily for 28 days, and serum aminotransferases and HCV RNA levels were measured. RESULTS: Both treatment groups showed significant decreases in absolute and percentage changes in serum alanine transaminase (ALT) from baseline to treatment day 28 (P<0.05). There was also a significant difference between incremental area under the curve for ALT between baseline and day 28 for the 40 mg treatment group against placebo (P<0.05). The differences in plasma ALT activity from baseline to day 28 in both mitoquinone groups compared with placebo did not reach significance (P>0.05). There was no change in HCV load on mitoquinone treatment. CONCLUSIONS: Administration of the mitochondria-targeted anti-oxidant mitoquinone significantly decreased plasma ALT and aspartate aminotransferase in patients with chronic HCV infection, and this suggests that mitoquinone may decrease necroinflammation in the liver in these patients. As mitochondrial oxidative damage contributes to many other chronic liver diseases, such as steatohepatitis, further studies using mitochondria-targeted anti-oxidants in HCV and other liver diseases are warranted.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1478-3231.2010.02250.x

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Research works printed but not linked: 5

  1. Reddy, 2009, Ribavirin, current role in the optimal clinical management of chronic hepatitis C, 50, 402
  2. Chandran, 2009, Doxorubicin inactivates myocardial cytochrome c oxidase in rats, cardioprotection by Mito-Q, 96, 1388
  3. Murphy, 2000, Drug delivery to mitochondria, the key to mitochondrial medicine, 41, 235
  4. Snow, 2008, Phase II study of the mitochondrial antioxidant mitoquinone for Parkinson's disease, Neurology, 70, A483
  5. Begriche, 2006, Mitochondrial dysfunction in NASH, causes, consequences and possible means to prevent it, 6, 1

Cited by

Sorted by citations

Items 201–300 of 379

Related

See all

Metadata

Authors
Gane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P.
Affiliations
  • Auckland City Hospital (NZ)
  • Waikato Hospital (NZ)
  • University of Otago (NZ)
  • MRC Mitochondrial Biology Unit (GB)
Corresponding author
Gane, Edward J.
ORCID
Venue
Liver International
Publisher
Wiley
Published
2010-05-18
Volume
30
Issue
7
Pages
1019-1026
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
DOI
10.1111/j.1478-3231.2010.02250.x
OpenAlex
W1623473717
Cited by
379
References
33
Citations by year
2026: 18 · 2025: 29 · 2024: 15 · 2023: 26 · 2022: 29 · 2021: 27 · 2020: 33 · 2019: 24 · 2018: 28 · 2017: 21 · 2016: 24 · 2015: 21 · 2014: 23 · 2013: 18 · 2012: 23
FWCI
12.81
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 1932 d)
Locations
  • Liver International (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatitis C virus research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
mitoquinone, chronic hepatitis C, mitochondria-targeted antioxidants, oxidative stress, mitochondrial damage, liver injury, alanine aminotransferase, aspartate aminotransferase, HCV RNA viral load, necroinflammation
MeSH terms
Administration, Oral, Adult, Alanine Transaminase, Antioxidants, Antiviral Agents, Aspartate Aminotransferases, Double-Blind Method, Female, Genotype, Humans, Interferons, Liver, Male, Middle Aged, Mitochondria, Liver, Organophosphorus Compounds, Ribavirin, RNA, Viral, Time Factors, Ubiquinone, Biomarkers, Hepacivirus, Treatment Outcome, Viral Load, Hepatitis C, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review